Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 61
Filter
5.
Eur J Surg Oncol ; 39(11): 1254-61, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23948705

ABSTRACT

BACKGROUND: The recurrence rate for stage I non-small cell lung cancer is high, with 20-40% of patients that relapse after surgery. The aim of this study was to evaluate new F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) derived parameters, such as standardized uptake value index (SUVindex), metabolic tumor volume (MTV) and total lesion glycolysis (TLG), as predictive factors for recurrence in resected stage I non-small cell lung cancer. METHODS: We retrospectively reviewed 99 resected stage I non-small cell lung cancer patients that were grouped by SUVindex, TLG and MTV above or below their median value. Disease free survival was evaluated as primary end point. RESULTS: The 5-year overall survival and the 5-year disease free survival rates were 62% and 73%, respectively. The median SUVindex, MTL and TLG were 2.73, 2.95 and 9.61, respectively. Patients with low SUVindex, MTV and TLG were more likely to have smaller tumors (p ≤ 0.001). Univariate analysis demonstrated that SUVindex (p = 0.027), MTV (p = 0.014) and TLG (p = 0.006) were significantly related to recurrence showing a better predictive performance than SUVmax (p = 0.031). The 5-year disease free survival rates in patients with low and high SUVindex, MTV and TLG were 84% and 59%, 86% and 62% and 88% and 60%, respectively. The multivariate analysis showed that only TLG was an independent prognostic factor (p = 0.014) with a hazard ratio of 4.782. CONCLUSION: Of the three PET-derived parameters evaluated, TLG seems to be the most accurate in stratifying surgically treated stage I non-small cell lung cancer patients according to their risk of recurrence.


Subject(s)
Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Glycolysis , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Positron-Emission Tomography , Adult , Aged , Aged, 80 and over , Analysis of Variance , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/surgery , Female , Fluorodeoxyglucose F18/metabolism , Humans , Kaplan-Meier Estimate , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/surgery , Male , Middle Aged , Neoplasm Recurrence, Local/diagnostic imaging , Neoplasm Recurrence, Local/metabolism , Neoplasm Staging , Odds Ratio , Positron-Emission Tomography/methods , Predictive Value of Tests , Prognosis , Radiopharmaceuticals/metabolism , Recurrence , Risk Assessment , Risk Factors , Tomography, X-Ray Computed
6.
Q J Nucl Med Mol Imaging ; 51(3): 214-23, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17464266

ABSTRACT

AIM: To evaluate the performance of the positron emission tomography (PET)/computed tomography (CT) Discovery-STE (D-STE) scanner for lesion detectability in two-dimensional (2D) and three-dimensional (3D) acquisition. METHODS: A NEMA 2001 Image-Quality phantom with 11 lesions (7-37 mm in diameter) filled with a solution of 18F (lesion/background concentration ratio: 4.4) was studied. 2D and 3D PET scans were sequentially acquired (10 min each) in list mode (LM). Each scan was unlisted into 4, 3 and 2-min scans. Ten [18F]FDG PET oncological patient studies were also evaluated. Each patient underwent a 3D PET/CT whole body scan, followed by a 2D PET scan (4 min LM) and a 3D PET scan (4 min LM) over a single field of view. Both 2D and 3D scans were unlisted in 3 and 2-min scans. Data were evaluated quantitatively by calculating quality measurements and qualitatively by two physicians who judged lesion detectability compared to statistical variations in background activity. RESULTS: Quantitative and qualitative evaluations showed the superiority of 3D over 2D across all measures of quality. In particular, lesion detectability was better in 3D than in 2D at equal scan times and 3D acquisition provided images comparable in quality to 2D in approximately half the time. Interobserver variability was lower in evaluation of 3D scans and lesion shape and volume were better depicted. CONCLUSION: In oncological applications, the D-STE system demonstrated good performance in 2D and 3D acquisition, while 3D exhibited better image quality, data accuracy and consistency of lesion detectability, resulting in shorter scan times and higher patient throughput.


Subject(s)
Image Enhancement/methods , Imaging, Three-Dimensional/methods , Neoplasms/diagnosis , Positron-Emission Tomography/methods , Subtraction Technique , Tomography, X-Ray Computed/methods , Whole Body Imaging/methods , Humans , Imaging, Three-Dimensional/instrumentation , Phantoms, Imaging , Positron-Emission Tomography/instrumentation , Reproducibility of Results , Sensitivity and Specificity , Tomography, X-Ray Computed/instrumentation , Whole Body Imaging/instrumentation
7.
Q J Nucl Med Mol Imaging ; 49(3): 267-79, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16172573

ABSTRACT

AIM: Implementation and validation of an automatic registration method based on mutual information (MI) for the integration of thoracic and abdominal positron emission tomography (PET)/computed tomography (CT) studies, with the purpose to facilitate in a clinical context the inclusion of PET metabolic information in conformal radiotherapy (RT). METHODS: Registration was obtained by modeling a rigid spatial transformation between CT and PET transmission studies. The registration method was based on Normalized Mutual Information (NMI), by iteratively transforming the PET volume, until its optimal alignment to the CT study is achieved, in correspondence of the maximum of NMI. To avoid entrapment in local maxima and to improve convergence speed we introduced a multiresolution scheme. Accuracy of the proposed approach was investigated in experimental data, relative to phantom and patient studies, acquired in conditions similar to clinical situations. RESULTS: In phantom studies the mean error in the 3D space is 3.6 mm (range 3-4 mm) in thoracic region and 3.2 mm (range 2.9-3.7 mm) in abdominal region, considerably less than PET spatial resolution. In patient studies the spatial mean error increases with respect to phantom studies (5.4 mm and 5.2 mm for thorax and abdomen, respectively) but remains comparable to the PET spatial resolution. The accuracy of spatial realignment was thus found adequate for the registration of PET/CT registration, if good patient repositioning was adopted. CONCLUSIONS: The proposed registration method, based on MI, was validated for the integration of PET/CT studies of patients candidate for thoracic and abdominal conformal RT. The method is automatic and provided with a user interface, thus suitable for clinical use.


Subject(s)
Abdominal Neoplasms/diagnosis , Abdominal Neoplasms/radiotherapy , Positron-Emission Tomography/methods , Radiotherapy, Conformal/methods , Subtraction Technique , Thoracic Neoplasms/diagnosis , Thoracic Neoplasms/radiotherapy , Tomography, X-Ray Computed/methods , Algorithms , Artificial Intelligence , Humans , Image Enhancement/methods , Image Interpretation, Computer-Assisted/methods , Imaging, Three-Dimensional/methods , Phantoms, Imaging , Positron-Emission Tomography/instrumentation , Radiotherapy, Computer-Assisted/methods , Reproducibility of Results , Sensitivity and Specificity , Tomography, X-Ray Computed/instrumentation
8.
Q J Nucl Med Mol Imaging ; 49(3): 259-66, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16172572

ABSTRACT

AIM: To prospectively evaluate the impact of coregistered positron emission tomography (PET) and computed tomography (CT) in 3D conformal radiotherapy (3D-CRT) planning in patients with non-small lung cancer (NSCLC). METHODS: Twenty-one patients (median age: 57 years; range: 42-80 years) referred to 3D-CRT for NSCLC were recruited. Positron emission tomography with 18F-fluorodeoxyglucose ([18F]FDG-PET) and conventional CT images were coregistered (PET/CT images) using a commercial software package based on surface matching technique. Neoplastic areas were contoured on [18F]FDG-PET images with the aid of the correspondent CT image by a nuclear medicine physician. CT images and their relative PET contours were then transferred to treatment planning system. A radiation oncologist firstly contoured clinical target volumes (CTV) on CT scan alone (CTV-CT), and then on coregistered PET/CT images (CTV-PET/CT). CTV-CT and CTV-PET/CT were compared for each patient; a difference higher than 25% was considered of clinical relevance. RESULTS: Three patients were shifted to palliative radiotherapy for metastatic disease or very large tumor size, showed by [18F]FDG-PET. Of the remaining 18 patients a CTV change, after inclusion of PET/CT data, was observed in 10/18 cases (55%): larger in 7/18 (range 33-279%) and smaller in 3/18 patients (range 26-34%), mainly due to inclusion or exclusion of lymph-nodal disease and to better definition of tumor extent. CTV changes smaller than 25% occurred in the remaining 8/18 patients. CONCLUSIONS: [18F]FDG-PET and CT images co-registration in radiotherapy treatment planning led to a change in CTV definition in the majority of our patients, which may significantly modify management and radiation treatment modality in these patients.


Subject(s)
Carcinoma, Non-Small-Cell Lung/diagnosis , Fluorodeoxyglucose F18 , Image Enhancement/methods , Imaging, Three-Dimensional/methods , Lung Neoplasms/diagnosis , Positron-Emission Tomography/methods , Subtraction Technique , Tomography, X-Ray Computed/methods , Adult , Aged , Aged, 80 and over , Feasibility Studies , Female , Humans , Image Interpretation, Computer-Assisted/methods , Male , Middle Aged , Neoplasm Staging/methods , Radiopharmaceuticals , Reproducibility of Results , Sensitivity and Specificity
9.
Ann Biomed Eng ; 32(10): 1399-408, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15535057

ABSTRACT

This work presents a method for CT and PET image registration, and multi-modal analysis, to optimize radiotherapy planning in lung cancer treatment. The method relies on an image registration technique based on fiducial external markers to realign, spatially, PET images with the CT spatial reference system. The method was set up for clinical use in radiotherapy, allowing minimal modifications to be introduced in the management of patients undergoing radiation treatment. The accuracy of the registration technique was evaluated on patient studies in terms of Target Registration Error and was found to be less than 6.40 mm. The method was applied in the treatment planning of five patients affected by non-small-cell lung cancer, revealing the usefulness of PET/CT integration in delineating the extension of both the tumor mass and the tissues involved in the neoplastic process. Moreover, the functional information provided by PET often led to alterations in the treatment planning, changing the size and/or direction of radiation portals. The proposed method for PET/CT integration has been confirmed as being useful for optimizing radiotherapy planning in lung cancer treatment.


Subject(s)
Image Enhancement/methods , Image Interpretation, Computer-Assisted/methods , Imaging, Three-Dimensional/methods , Lung Neoplasms/diagnosis , Lung Neoplasms/radiotherapy , Radiotherapy Planning, Computer-Assisted/methods , Subtraction Technique , Algorithms , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/radiotherapy , Humans , Lung Neoplasms/diagnostic imaging , Pattern Recognition, Automated/methods , Positron-Emission Tomography/methods , Reproducibility of Results , Sensitivity and Specificity , Tomography, X-Ray Computed/methods
10.
Q J Nucl Med Mol Imaging ; 48(2): 66-75, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15243404

ABSTRACT

In the last years positron emission tomography (PET) with 18F-fluorodeoxyglucose ([18F]FDG) has become an established technique for the staging and follow-up of a wide variety of neoplasms. As PET imaging is based on the physiological mediated distribution of the administered tracer, rather than on anatomic and structural characteristics of tissue, the addition of CT imaging to PET improves the interpretation of PET images. Recently, integrated PET/CT scanners have been developed that can produce directly functional PET and anatomical CT data 1 session, without moving the patient and with minimal delay between the reconstruction and fusion of the 2 image data sets. In addition, CT images are also being used for attenuation correction in the reconstruction process of the PET emission data. A brief review of the most relevant technical characteristics of 3 PET/CT systems, which represent the state of the art of this technology, are described. Furthermore an overview of PET/CT acquisition protocols and clinical applications of PET/CT in oncology are described. Overall, advantages of PET/CT over PET that may influence the clinical routine, have been identified as a) the shorter image acquisition time with benefit on patients throughput and on patient compliance, b) the better accuracy in anatomically localizing focal areas of abnormal tracer uptake and defining tumor extent and c) the possibility to stage a disease in 1 single step.


Subject(s)
Neoplasms/diagnosis , Tomography, Emission-Computed , Tomography, X-Ray Computed , Fluorodeoxyglucose F18 , Humans , Image Processing, Computer-Assisted , Neoplasm Staging , Radiopharmaceuticals , Tomography Scanners, X-Ray Computed
12.
J Thorac Cardiovasc Surg ; 126(6): 1906-10, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14688704

ABSTRACT

OBJECTIVE: F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) is now a procedure of proven clinical value in the staging of primary lung cancer. This study evaluated the role of PET in the preoperative assessment of resectable lung metastases. METHODS: Eighty-six patients with previously treated malignancy and proven or suspected lung metastases, deemed resectable at computed tomography scan, were investigated with 89 preoperative PET procedures. Primary tumor sites were: gastrointestinal in 32 cases, sarcoma in 13, urologic in 14, breast in 8, head and neck in 7, gynecologic in 5, thymus in 5, other in 5. Seventy lung resections were performed in 68 patients of whom only 54 proved to be lung metastasis, 7 were primary lung tumors, and 9 were benign lesions. RESULTS: In 19 cases (21%) lung surgery was excluded on the basis of PET scan results due to extrapulmonary metastases (11 cases), primary site recurrence (2), mediastinal adenopathy (2), or benign disease (4). All mediastinal node metastases (7 cases) were detected by PET with a sensitivity, accuracy, and negative predictive value for mediastinal staging of 100%, 96%, and 100%, respectively, versus 71%, 92%, and 95% of the computed tomography scan. In the group of patients who underwent lung resection, PET sensitivity for detection of lung metastasis was 87%. CONCLUSIONS: PET scan proved to be a valuable staging procedure in patients with clinically resectable lung metastasis and changed the therapeutic management in a high proportion of cases.


Subject(s)
Fluorodeoxyglucose F18 , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/secondary , Radiopharmaceuticals , Tomography, Emission-Computed , Female , Humans , Lung Neoplasms/surgery , Lymphatic Metastasis , Male , Middle Aged , Predictive Value of Tests , Sensitivity and Specificity
13.
Q J Nucl Med ; 47(2): 77-84, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12865867

ABSTRACT

AIM: To determine the additional value of [(18)F]FDG-PET in combination with computed tomography (CT) over CT used alone, for evaluating ovarian cancer patients after primary treatment. METHODS: Twenty-five women (mean age: 53.6 years) had primary debulking surgery followed by chemotherapy for histologically proven ovarian carcinoma. At initial diagnosis, the tumor types were papillary serous adenocarcinoma (n=20), endometroid carcinoma (n=3), mixed mullerian tumor (n=1), and granulosa cell tumor (n=1). All patients underwent [(18)F]FDG-PET and contrast enhanced CT examinations, within 30 days of the completion of chemotherapic treatment. [(18)F]FDG-PET images were interpreted with the knowledge of CT findings (PET+CT); conversely, CT images were evaluated with no knowledge of the [(18)F]FDG-PET results. Within 7 day of imaging studies, 2(nd)-look laparoscopy (n=7) or laparotomy (n=18) was performed for histological confirmation. In all cases, imaging findings were then correlated with results of histopathologic examination. RESULTS: Of the 23 neoplastic viable lesions, all histologically confirmed, 16 could be detected by CT alone and 19 by PET+CT. An inflammatory lymph-node was misdiagnosed as viable tumor with both PET+CT and CT alone; an area of scar tissue in the presacral region was also misinterpreted as malignant tissue with CT alone. Overall lesion-based sensitivity, specificity and accuracy in assessing focal areas of residual tumor were as follows: 69.56%, 83.33%, 74.28% for CT, and 82.60%, 91.67%, 85.71% for PET+CT. The negative predictive value of PET+CT was markedly higher (73.33%), compared to that of CT alone (58.82%). CONCLUSION: PET used in combination with CT allows to accurately assess tumor response. A major advantage of PET+CT over CT alone is in excluding the presence of residual viable lesions after treatment.


Subject(s)
Fluorodeoxyglucose F18 , Neoplasm Recurrence, Local/diagnostic imaging , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/therapy , Subtraction Technique , Tomography, Emission-Computed/methods , Tomography, X-Ray Computed/methods , Adult , Aged , Female , Humans , Middle Aged , Ovarian Neoplasms/diagnostic imaging , Radiopharmaceuticals , Reproducibility of Results , Sensitivity and Specificity , Treatment Outcome
14.
Q J Nucl Med ; 47(2): 90-100, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12865869

ABSTRACT

AIM: This study was aimed at assessing the clinical performances of a NaI(Tl) crystal 3D PET scanner, C-PET (ADAC-UGM), using a multi-ring 2D BGO PET scanner (multi-ring PET), as a reference. METHODS: Thirty-seven oncological patients were studied in sequence with multi-ring PET and C-PET, within 30 days of a CT study. In order to assess the behaviour of C-PET in relation to acquisition count rate, patients were divided into 3 groups according to the count rate at the time of the C-PET scan acquisition. Group A (n=21): 3000-5000 kcounts/sec (recommended count rate range); Group B (n=8): <3000 Kcounts/sec and Group C (n=8): >5000 Kcounts/sec. RESULTS: The number of lesions detected by multi-ring PET and C-PET, classified according to size, was compared. For Group A and Group B there was a good agreement between C-PET and multi-ring PET in terms of lesion detectability (relative sensitivity: 99.9% and 96.0%, respectively), while for Group C the relative sensitivity of C-PET was 61.9%. CONCLUSION: Optimal performances of the C-PET scanner can thus be obtained at a count rate within or below the recommended range. Despite a lower lesion/background contrast resulting from a high scatter and random noise, the sensitivity of C-PET in detecting hypermetabolic lesions is comparable to that of multi-ring PET. These findings are discussed in relation to the physical performance of the two scanners and particularly in relation to the 3D vs 2D acquisition modality.


Subject(s)
Equipment Failure Analysis , Fluorodeoxyglucose F18 , Imaging, Three-Dimensional/instrumentation , Neoplasms/diagnostic imaging , Tomography, Emission-Computed/instrumentation , Adult , Aged , Humans , Imaging, Three-Dimensional/methods , Middle Aged , Neoplasms/pathology , Radiopharmaceuticals , Reproducibility of Results , Sensitivity and Specificity , Sodium Iodide , Tomography, Emission-Computed/methods , Transducers
15.
J Urol ; 169(4): 1337-40, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12629355

ABSTRACT

PURPOSE: We compared [11C]choline-positron emission tomography (PET) with [18F]fluorodeoxyglucose-PET for re-staging prostate cancer in a group of 100 patients. MATERIALS AND METHODS: A total of 100 consecutive patients referred for whole body [18F]fluorodeoxyglucose-PET for clinical prostate re-staging after radical treatment for prostate cancer were retrospectively included in the study. Mean prostate specific antigen (PSA) was 6.57 ng./ml. In all cases [11C]choline-PET was also performed. PET studies were done with a multiring device 5 minutes after intravenous injection of approximately 370 MBq. [11C]choline and 60 minutes after injection of approximately 370 MBq. [18F]fluorodeoxyglucose. PET findings were compared with those obtained with different conventional imaging and with PSA assessed at the time of PET and 1 year later. RESULTS: Areas of abnormal focal increases were noted in 47% of patients on [11C]choline-PET and in 27% on [18F]fluorodeoxyglucose-PET. Of the 100 patients 49 had positive conventional imaging findings. All except 14 [11C]choline-PET findings were concordant with conventional imaging, including 6 negative and 8 positive conventional imaging results. All except 1 [11C]choline-PET negative cases also had negative conventional imaging after 1 year. PSA at 1 year remained stable or decreased in 80% and 62% of [11C]choline-PET negative and positive cases, respectively. CONCLUSIONS: [11C]choline-PET seems to be useful for re-staging prostatectomy cases with increasing serum PSA levels. It is superior to [18F]fluorodeoxyglucose-PET and complementary to conventional imaging but with the advantage of staging disease at a single step.


Subject(s)
Carbon Radioisotopes , Choline , Fluorodeoxyglucose F18 , Prostatic Neoplasms/pathology , Tomography, Emission-Computed , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , Humans , Male , Middle Aged , Neoplasm Staging , Prostate/diagnostic imaging , Prostate/pathology , Prostate-Specific Antigen/blood , Prostatectomy , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/radiotherapy , Prostatic Neoplasms/surgery , Sensitivity and Specificity
17.
Br J Cancer ; 86(9): 1391-5, 2002 May 06.
Article in English | MEDLINE | ID: mdl-11986769

ABSTRACT

Neoangiogenesis and enhanced glucose metabolism in neoplasms are likely to be activated by the same biochemical stimulus; hypoxia. A correlation between these two parameters has been postulated. The objective of this study was to evaluate the relationship between Fluoro-desoxi-glucose uptake at positron emission tomography scan and angiogenesis in lung metastasis. Fluoro-desoxi-glucose activity, expressed as a standard uptake value, and microvessel intratumoural density, were retrospectively calculated in a series of 43 lung metastasis resected in 19 patients. Primary sites were colorectal cancer in 16 metastases, sarcoma in eight, gynaecological in four and other sites in 15. The correlation between the two parameters was tested by logistic regression and multivariate analysis. Positron emission tomography scan was positive in 17 patients (sensitivity 89%). No correlation was observed between standard uptake value and microvessel intratumoural density in this series of lung metastasis. Positron emission tomography negative and positive nodules presented comparable value of microvessel intratumoural density (12.9 vs 11.3). Standard uptake value was significantly correlated with nodules size and was higher in colon cancer metastasis than in sarcoma ones. Microvessel intratumoural density was independent from nodule size but significantly higher in sarcoma than in colon cancer metastasis. The lack of correlation was confirmed by multivariate analysis after adjustment for tumour type and nodules size. The present study demonstrated that positron emission tomography scan is positive in a high proportion of patients regardless of microvessel density. Glucose uptake and angiogenesis appear to be independent biological features in lung metastasis. This observation may have implications for future antiangiogenic therapies.


Subject(s)
Fluorodeoxyglucose F18/therapeutic use , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/secondary , Neoplasm Metastasis/physiopathology , Neovascularization, Pathologic/physiopathology , Radiopharmaceuticals/therapeutic use , Adult , Aged , Colorectal Neoplasms/pathology , Female , Fluorodeoxyglucose F18/pharmacokinetics , Genital Neoplasms, Female/pathology , Humans , Male , Middle Aged , Prognosis , Radiopharmaceuticals/pharmacokinetics , Retrospective Studies , Sarcoma/secondary , Tomography, Emission-Computed
19.
Ugeskr Laeger ; 162(27): 3846-8, 2000 Jul 03.
Article in Swedish | MEDLINE | ID: mdl-10920697

ABSTRACT

Glucose consumption in tissue can be measured using positron emission tomography (PET) and 18F-deoxyglucose (18FDG). Malignant tumors rely largely on anaerobic glycolysis and show very rapid glucose consumption, and can therefore be imaged using PET and 18FDG. PET has been shown to be useful in the evaluation of patients with e.g. lung cancer, colo-rectal cancer, malignant melanoma and malignant lymphoma, in terms of both diagnostic accuracy and cost-effectiveness. The clinical use of PET for workup of cancer patients is increasing rapidly in North America as well as in the European Union, but Sweden is lagging behind.


Subject(s)
Neoplasms/diagnostic imaging , Tomography, Emission-Computed , Fluorine Radioisotopes , Fluorodeoxyglucose F18 , Humans , Male , Middle Aged , Neoplasms/diagnosis , Neoplasms/metabolism , Rectal Neoplasms/diagnostic imaging , Sweden , Tomography, Emission-Computed/economics , Tomography, Emission-Computed/statistics & numerical data , United States
20.
Lakartidningen ; 97(16): 1946-8, 2000 Apr 19.
Article in Swedish | MEDLINE | ID: mdl-10826352

ABSTRACT

Glucose consumption in tissue can be measured using positron emission tomography (PET) and 18F-deoxyglucose (18FDG). Malignant tumors rely largely on anaerobic glycolysis and show very rapid glucose consumption, and can therefore be imaged using PET and 18FDG. PET has been shown to be useful in the evaluation of patients with e.g. lung cancer, colo-rectal cancer, malignant melanoma and malignant lymphoma, in terms of both diagnostic accuracy and cost-effectiveness. The clinical use of PET for workup of cancer patients is increasing rapidly in North America as well as in the European Union, but Sweden is lagging behind.


Subject(s)
Neoplasms/diagnostic imaging , Tomography, Emission-Computed , Deoxyglucose/metabolism , Fluorine Radioisotopes , Glucose/metabolism , Humans , Lung Neoplasms/diagnostic imaging , Male , Middle Aged , Neoplasms/diagnosis , Neoplasms/metabolism , Rectal Neoplasms/diagnostic imaging , Sweden , Tomography, Emission-Computed/economics , Tomography, Emission-Computed/statistics & numerical data , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...